| Autor: |
Erden, A., Karakas, O., Armagan, B., Guven, S. C., Ozdemir, B., Atalar, E., Apaydin, H., Usul, E., Ates, I., Omma, A., Kucuksahin, O. |
| Předmět: |
|
| Zdroj: |
Bratislava Medical Journal / Bratislavské Lekárske Listy; 2022, Vol. 123 Issue 2, p120-124, 5p |
| Abstrakt: |
BACKGROUND: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS). METHODS: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR-positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records. RESULTS: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection. CONCLUSION: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33). [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
